title: Raloxifene: a review of its use in the prevention of invasive breast cancer.
abstract: Raloxifene (Evista) is a second-generation selective estrogen receptor modulator (SERM) that functions as an estrogen antagonist on breast and uterine tissues, and an estrogen agonist on bone. It is available in many countries worldwide for the treatment and prevention of osteoporosis in postmenopausal women, and has also been approved in the US for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis or postmenopausal women at increased risk of invasive breast cancer.Raloxifene reduces the risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer and in postmenopausal women with osteoporosis. In addition, it is a well established agent for the prevention and treatment of osteoporosis. There was no significant difference between raloxifene and tamoxifen in the reduction in the risk of invasive breast cancer achieved in postmenopausal women at high risk of such cancer. Raloxifene was associated with an increased, albeit rare, risk of venous thromboembolism across several placebo-controlled trials and an increased risk of fatal stroke in one placebo-controlled trial in postmenopausal woman at increased risk for major coronary events. However, raloxifene was associated with a lower risk of venous thromboembolic events and cataracts than tamoxifen in a head-to-head trial. The choice of chemoprevention agent must consider a risk-benefit assessment for each individual patient. In this context, raloxifene is a valuable option for the prevention of invasive breast cancer in postmenopausal women with osteoporosis or at high risk of invasive breast cancer.
authors.affiliation: Wolters Kluwer Health | Adis, Auckland, New Zealand. demail@adis.co.nz
authors.forename: Marit D
authors.initials: MD
authors.lastname: Moen
authors.forename: Gillian M
authors.initials: GM
authors.lastname: Keating
mesh_terms: D001943:Breast Neoplasms / Q000473:pathology / Q000517:prevention & control* / Q000523:psychology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000517:prevention & control; D015663:Osteoporosis, Postmenopausal / Q000150:complications; D011788:Quality of Life; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride
references.citation: J Natl Cancer Inst. 2004 Dec 1;96(23):1751-61
references.pmid: 15572757
references.citation: J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86
references.pmid: 2593165
references.citation: J Natl Cancer Inst. 2001 Mar 7;93(5):334-5
references.pmid: 11238688
references.citation: J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88
references.pmid: 9747868
references.citation: JAMA. 2002 Jan 9;287(2):216-20
references.pmid: 11779264
references.citation: J Natl Cancer Inst. 2007 Sep 5;99(17):1282-3, 1289
references.pmid: 17728206
references.citation: Breast Cancer Res Treat. 2006 Jul;98(2):167-72
references.pmid: 16538534
references.citation: Clin Cancer Res. 2006 Sep 1;12(17):5242-7
references.pmid: 16951244
references.citation: Gynecol Endocrinol. 2001 Jun;15(3):225-33
references.pmid: 11447735
references.citation: Menopause. 2003 Jul-Aug;10(4):337-44
references.pmid: 12851517
references.citation: Curr Med Res Opin. 2005 Sep;21(9):1441-52
references.pmid: 16197663
references.citation: Am J Ther. 2006 Jul-Aug;13(4):337-48
references.pmid: 16858170
references.citation: J Natl Cancer Inst. 1999 Sep 15;91(18):1541-8
references.pmid: 10491430
references.citation: JAMA. 1998 May 13;279(18):1445-51
references.pmid: 9600478
references.citation: JAMA. 2006 Jun 21;295(23):2742-51
references.pmid: 16754728
references.citation: Metabolism. 2005 Jul;54(7):939-46
references.pmid: 15988705
references.citation: Life Sci. 1983 Jun 20;32(25):2869-75
references.pmid: 6406781
references.citation: Arch Intern Med. 2000 Dec 11-25;160(22):3444-50
references.pmid: 11112238
references.citation: JAMA. 2002 Feb 20;287(7):847-57
references.pmid: 11851576
references.citation: Am J Obstet Gynecol. 2003 Feb;188(2):389-94
references.pmid: 12592245
references.citation: Eur J Obstet Gynecol Reprod Biol. 1999 Jul;85(1):23-9
references.pmid: 10428318
references.citation: JAMA. 1999 Aug 18;282(7):637-45
references.pmid: 10517716
references.citation: JAMA. 2006 Jun 21;295(23):2727-41
references.pmid: 16754727
references.citation: J Natl Cancer Inst. 2008 Jun 18;100(12):831-3
references.pmid: 18544739
references.citation: Breast Cancer Res Treat. 2008 Apr;108(3):435-53
references.pmid: 17554628
references.citation: BJOG. 2008 May;115(6):773-9
references.pmid: 18355366
references.citation: N Engl J Med. 2006 Jul 13;355(2):125-37
references.pmid: 16837676
references.citation: Maturitas. 2008 Jun 20;60(2):92-107
references.pmid: 18534794
references.citation: Menopause. 2002 Mar-Apr;9(2):110-6
references.pmid: 11875329
references.citation: Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):961-6
references.pmid: 11535548
references.citation: Clin Ther. 2004 Jun;26(6):830-40
references.pmid: 15262454
references.citation: Obstet Gynecol. 2000 Jan;95(1):95-103
references.pmid: 10636510
references.citation: Int Semin Surg Oncol. 2007 Jul 23;4:18
references.pmid: 17645796
references.citation: N Engl J Med. 1997 Dec 4;337(23):1641-7
references.pmid: 9385122
references.citation: J Natl Cancer Inst. 2006 Sep 6;98(17):1172-3
references.pmid: 16954464
references.citation: JAMA. 2006 Jun 21;295(23):2784-6
references.pmid: 16754726
references.citation: Breast Cancer Res Treat. 2001 Jan;65(2):125-34
references.pmid: 11261828
references.citation: J Clin Oncol. 2007 Nov 1;25(31):4967-73
references.pmid: 17971595
references.citation: Br J Pharmacol. 2007 Jan;150(1):3-4
references.pmid: 17115068
references.citation: J Clin Endocrinol Metab. 2000 Jun;85(6):2197-202
references.pmid: 10852452
references.citation: J Bone Miner Res. 2002 Feb;17(2):341-8
references.pmid: 11811565
references.citation: Br J Clin Pharmacol. 2005 Apr;59(4):479-82
references.pmid: 15801944
references.citation: Anticancer Res. 2006 Jan-Feb;26(1B):735-44
references.pmid: 16739346
references.citation: Am J Psychiatry. 2005 Apr;162(4):683-90
references.pmid: 15800139
references.citation: Drugs Aging. 1998 Apr;12(4):335-41; discussion 342
references.pmid: 9571395
references.citation: Int J Clin Pract. 2007 Dec;61(12):2051-63
references.pmid: 17892469
references.citation: Drugs. 2000 Aug;60(2):379-411
references.pmid: 10983739
references.citation: JAMA. 1999 Jun 16;281(23):2189-97
references.pmid: 10376571
references.citation: J Natl Cancer Inst. 2001 Jan 3;93(1):51-6
references.pmid: 11136842
references.citation: Cancer. 2000 May 1;88(9):2047-53
references.pmid: 10813716
references.citation: J Clin Oncol. 2001 Jun 15;19(12):3111-6
references.pmid: 11408508
references.citation: Cancer Res. 1985 Feb;45(2):584-90
references.pmid: 3967234
references.citation: Clin Pharmacokinet. 2003;42(4):361-72
references.pmid: 12648026
references.citation: Biochem Pharmacol. 2006 May 14;71(10):1459-69
references.pmid: 16554039
references.citation: Br J Cancer. 2001 Dec 14;85(12):1838-41
references.pmid: 11747323
references.citation: Arch Intern Med. 2004 Apr 26;164(8):871-9
references.pmid: 15111373
references.citation: Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1468-73
references.pmid: 14693739
references.citation: J Fam Pract. 2004 Oct;53(10):789-96
references.pmid: 15469774
references.citation: J Natl Cancer Inst. 1996 Jan 17;88(2):123-5
references.pmid: 8537973
references.citation: Arch Intern Med. 2001 Jul 9;161(13):1639-44
references.pmid: 11434796
references.citation: Expert Opin Pharmacother. 2006 Nov;7(16):2301-7
references.pmid: 17059385
references.citation: J Clin Endocrinol Metab. 1997 Oct;82(10):3425-9
references.pmid: 9329380
references.citation: Curr Med Res Opin. 2008 Mar;24(3):807-13
references.pmid: 18254988
references.citation: Pharm Res. 2001 Jul;18(7):1024-8
references.pmid: 11496940
references.citation: Expert Opin Drug Saf. 2008 May;7(3):259-70
references.pmid: 18462184
references.citation: Oncology. 1988;45(5):344-5
references.pmid: 3412740
references.citation: J Natl Cancer Inst. 2008 Jun 18;100(12):854-61
references.pmid: 18544744
references.citation: N Engl J Med. 2001 Apr 19;344(16):1207-13
references.pmid: 11309635